

## NEEDLE &amp; ROSENBERG

## IMPORTANT FAX DOCUMENT

NEEDLE & ROSENBERG PC  
SUITE 1000  
999 PEACHTREE STREET  
ATLANTA, GEORGIA 30309-3915  
678-420-9300  
NEEDLEROSENBERG.COM

DATE March 16, 2004  
NAME Examiner Myron G. Hill  
COMPANY U.S. Patent and Trademark Office  
FAX NUMBER (571) 273-0901

FROM Teresa R. Spratt for Gwendolyn D. Spratt  
REFERENCE NO. 14114.0331U2  
OUR FAX NUMBER 678-420-9301  
NUMBER OF PAGES 5

In re Application of

Switzer et al.

Application No. 10/018,627

Filed: March 3, 2003

For: "ISOLATION OF A HUMAN  
RETROVIRUS"

Group Art Unit: 1648

Examiner: Hill, Myron G.

Confirmation No. 5188

## CONFIDENTIALITY NOTE

The information which follows and is transmitted herewith is attorney privileged, trade secret and confidential information intended only for viewing and use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any review, use, communication, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address.

189672.4DOC

**ATTORNEY DOCKET NO. 14114.0331U2  
PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Switzer <i>et al.</i>	)	Group Art Unit: 1648
	)	
Application No. 10/018,627	)	Examiner: Hill, Myron G.
	)	
Filed: March 3, 2003	)	Confirmation No. 5188
	)	
For: "ISOLATION OF A HUMAN RETROVIRUS"	)	

**SECOND SUPPLEMENTAL AMENDMENT TO OFFICE ACTION****VIA FACSIMILE (571) 273-0901**

**ATTN: Examiner M. Hill**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859

Sir:

This Second Supplemental Amendment to Office Action filed under 37 C.F.R. § 1.113 is responsive to the Office Action dated December 16, 2003 issued regarding the above-referenced patent application.

**Amendments to the claims** are reflected in the listing of claims which begins on page 2 of this response.

**Remarks** begin on page 3 of this response.